Overview of Residual Risk and Pathophysiological Targets for Devices to Treat Chronic HF

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker’s Bureau - Axon Therapies; Viscardia; Bayer AG; Boston Scientific Corporation; CVRx; Daxor; Zoll; Bodyport; Cadence; Gradient; Intershunt; Alleviant; NXT; FIRE1; Endotronix, Inc.; Novo Nordisk